

Memphasys secures R&D Tax Rebate loan

HIGHLIGHTS

- **\$472,236 received via a short-term loan against its 2025 R&D Tax Rebate, with R&D Rebate of ~ \$900k expected to be received in September 2024, and**
- **Funds to be used to progress Felix™ System commercial activities following completion of clinical trial, as well as servicing working capital requirements.**

Australian reproductive biotechnology company Memphasys Limited (ASX: MEM) (the Company) is pleased to advise that it has received \$472,236 via a loan against its 2024/25 R&D Tax Rebate, with loan funds received today and balance of R&D Rebate of ~\$900k expected to be received in September 2025.

The loan is secured by and repayable out of the 2025 R&D Tax Rebate and attracts a fixed 15% per annum interest rate. It matures on 30 November 2025, however, can be extended by agreement between the lender and Memphasys.

Funds will primarily be used to assist the Company in further commercial activities following completion of its Felix™ System clinical trial and CE Mark registration.

MEM CEO/ED, Dr David Ali said, *"We are pleased to have secured these funds to support the advancement of our commercial activities. Memphasys prudently manages its cashflow and will continue to assess all avenues to increase funding available for commercialising Felix™ and its wider development portfolio."*

ENDS

Approved for release by the Board of Memphasys Limited.

For further information, please contact:

Dr. David Ali
CEO and Executive Director
Memphasys Limited
Tel: +61 2 8415 7300